Compared to statins, the treatment with PCSK9 inhibitors was associated with a statistically significant decrease in cardiovascular events (RR 0.87; 95% CI: 0.83–0.91), non-fatal myocardial infarction (RR 0.86; 95% CI: 0.78–0.96), and ischaemic stroke (RR 0.75; 95% CI: 0.64–0.87). The same was not always true in comparison with ezetimibe. PCSK9 inhibitors were not associated with decrease of cardiovascular death (RR 0.96; 95% CI: 0.85–1.08) or all-cause mortality (RR 0.95; 95% CI: 0.86–1.05). Here, PCSK9 is linked to myocardial infarction.